Categories
Change Password!
Reset Password!
In MASLD, statins significantly reduce the long-term risk of death, liver-linked complications, and worsening of liver stiffness.
In a cohort study published in “BMJ Journals”, individuals with metabolic-associated steatotic liver disease (MASLD) on statins exhibited a lower risk of overall mortality, liver stiffness escalation, and liver-related clinical events. Statins are known for their benefits beyond cholesterol control. Hence, this study investigated their use for MASLD management. A cohort of 7,988 MASLD patients was tracked over a median of 4.6 years, with data from at least two vibration-controlled transient elastography exams.
Researchers used Cox regression to evaluate how statin use affected all-cause mortality, liver-related clinical events, and liver stiffness changes, differentiating between those with compensated advanced chronic liver disease (cACLD) and those without. Out of 7,988 patients, 40.5% used statins. In 17% of cases, cACLD was present. Statin use was linked to a lower risk of all-cause mortality (adjusted hazard ratio [HR]=0.233) and liver-related events (adjusted HR=0.380).
It also reduced liver stiffness progression in both non-cACLD (adjusted HR=0.450) and cACLD (adjusted HR=0.542). However, statins did not significantly impact liver stiffness regression (adjusted HR=0.914). In conclusion, statin use is related to remarkably lower risks of all-cause mortality, liver-related events, and liver stiffness progression in MASLD patients, though it doesn’t affect liver stiffness regression.
BMJ Journals
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Xiao-Dong Zhou et al.
Comments (0)